Albert Lockhart

Professor

  • 3919 Citations
1977 …2021

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Albert Lockhart is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    • 3919 Citations
    • 87 Article
    • 19 Review article
    • 5 Comment/debate
    • 1 Letter

    First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

    Papadopoulos, K. P., Johnson, M. L., Lockhart, A. C., Moore, K., Falchook, G. S., Formenti, S. C., Naing, A., Carvajal, R. D., Rosen, L. S., Weiss, G. J., Leidner, R. S., Li, J., Paccaly, A., Feng, M., Stankevich, E., Lowy, I., Fury, M. G. & Crittenden, M. R., Mar 1 2020, In : Clinical cancer research : an official journal of the American Association for Cancer Research. 26, 5, p. 1025-1033 9 p.

    Research output: Contribution to journalArticle

    Open Access

    Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma

    Grierson, P., Teague, A., Suresh, R., Lim, K. H., Amin, M., Pedersen, K., Tan, B., Huffman, J., Boice, N., Du, L., Liu, J., Lockhart, A. C. & Wang-Gillam, A., Feb 1 2020, In : Journal of Gastrointestinal Oncology. 11, 1, p. 61-67 7 p.

    Research output: Contribution to journalArticle

    A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors

    Weekes, C., Lockhart, A. C., Lee, J. J., Sturm, I., Cleton, A., Huang, F. & Lenz, H. J., Jan 1 2019, In : International Journal of Cancer.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)

    Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 others, Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 28 2019, In : Nature. 566, 7745, p. E11-E12

    Research output: Contribution to journalComment/debate

  • 2 Scopus citations

    Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

    Faessel, H., Nemunaitis, J., Bauer, T. M., Lockhart, A. C., Faller, D. V., Sedarati, F., Zhou, X., Venkatakrishnan, K. & Harvey, R. D., Jan 1 2019, In : British Journal of Clinical Pharmacology.

    Research output: Contribution to journalArticle

    Open Access